Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Ralph Alvarez acquired 15,083 shares of Eli Lilly common stock through a deferral plan, while also disposing of 54,689.496 shares.

Summary

• Ralph Alvarez, a director at Eli Lilly & Co, acquired 15,083 shares of common stock on December 16, 2024.
• These shares were acquired through a deferral plan in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Alvarez's separation from service.
• Mr. Alvarez also disposed of 54,689.496 shares of common stock.
• The price of the acquired shares was $779.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to director compensation. It is neither particularly positive nor negative.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice in the pharmaceutical industry.
• Many companies, such as Pfizer (PFE) and Johnson & Johnson (JNJ), offer similar compensation structures to their directors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Form 4, LLY